Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

797.45 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,263
Open 797.45
Bid (Size) 800.00 (1)
Ask (Size) 803.00 (1)
Prev. Close 797.45
Today's Range 797.45 - 797.45
52wk Range 561.65 - 972.53
Shares Outstanding N/A
Dividend Yield 0.57%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eli Lilly Just Hit a Milestone That Disappointed. Here's Why You Should Still Buy the Stock.
The market's perception of the pharmaceutical company has undeniably shifted. 
Via The Motley Fool
Smaller Cap Biotechs Are In Season: How Are We Doing?
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets

Performance

YTD
+34.66%
+34.66%
1 Month
-12.72%
-12.72%
3 Month
-5.66%
-5.66%
6 Month
+3.36%
+3.36%
1 Year
+28.80%
+28.80%

More News

Read More
Compounded Versions Of Weight Loss And Diabetes Drugs Led To Death And Hospitalization, Novo Nordisk Says It Is Aware
Via Benzinga
Topics Death
Exposures Death Product Safety
Market Whales and Their Recent Bets on LLY Options
Via Benzinga
Eli Lilly Posts a Huge Earnings Miss. Should Investors Be Worried?
Via The Motley Fool
Topics Earnings
Exposures Financial
Assessing Eli Lilly's Performance Against Competitors In Pharmaceuticals Industry
Via Benzinga
Missed Out on Eli Lilly? Buy This Amazing Growth Stock Instead
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Is Eli Lilly a Buy? Analyst Confidence Grows for 2025
Via MarketBeat
Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required
Via Talk Markets
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
Via Benzinga
What's Going On With Hims & Hers Health Stock Monday?
Via Benzinga
As Race To Best 'Miracle' Obesity Drug Heats Up, Ozempic Maker Novo Nordisk Tests New Hybrid Drug That Can Reduce Weight Up To 25%
Via Benzinga
Viking Therapeutics Surges, Set To Break Out On Latest Obesity Drug Data
Via Investor's Business Daily
Could This Near Trillion-Dollar Stock Be a Millionaire Maker?
Via The Motley Fool
Market Volatility Soars Ahead Of Elections, Tech Earnings Mixed, Strikes And Hurricanes Knock Employment Down: This Week In The Markets
Via Benzinga
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Via Investor's Business Daily
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
Via Investor's Business Daily
Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
Via Benzinga
Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip
Via The Motley Fool
Topics Earnings
Exposures Financial
Viking Therapeutics Stock: A Pre-Election Bet Worth Considering
Via MarketBeat
Nasdaq Tumbles Over 100 Points Ahead Of Big Tech Earnings: Fear & Greed Index Remains In 'Greed' Zone
Via Benzinga
Are Eli Lilly's Lowered Expectations a Reason to Sell?
Via The Motley Fool
Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO
Via Investor's Business Daily
AMD Earnings Show Power Of Nvidia Software, ADP Data Defies Expectations
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.